Clinical Edge Journal Scan

Leisure-time physical activity may lower premenopausal breast cancer risk


 

Key clinical point: Higher levels of leisure-time physical activity reduced the risk for premenopausal breast cancer (BC) significantly, with more prominent effects observed for human epidermal growth factor receptor 2 (HER2)-enriched BC.

Major finding: At a median follow-up of 11.5 years, higher vs lower levels (90 th vs 10 th percentile) of leisure-time physical activity were associated with a 10% reduced risk for overall BC (adjusted hazard ratio [aHR] 0.90; P < .001) and a substantial 45% reduction in the risk for HER2-enriched BC (aHR 0.55; 95% CI 0.37-0.82).

Study details: Findings are from a pooled analysis of the data from 19 prospective cohorts that included a total of 547,601 premenopausal women with 10,231 incident cases of in situ or invasive BC.

Disclosures: This study was supported by the Intramural Research Program of the US National Cancer Institute and US National Institutes of Health, and other sources. Some authors declared employment with; holding patents, stocks, and other ownership interests in; serving in consulting or advisory roles for; or receiving honoraria or research funding from various sources.

Source: Timmins IR et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J Clin Oncol. 2023 (Dec 11). doi: 10.1200/JCO.23.01101

Recommended Reading

No Added Benefit From Chemo in This Breast Cancer Subtype
MDedge Hematology and Oncology
Magnetic Seeds or Guidewires for Breast Cancer Localization?
MDedge Hematology and Oncology
Clinical Exams Fall Short in Second Breast Cancer Detection
MDedge Hematology and Oncology
BC axillary dissection may be unnecessary for isolated tumor cells after NAC
MDedge Hematology and Oncology
Benign breast disease on percutaneous biopsy increases breast cancer risk
MDedge Hematology and Oncology
Carboplatin + atezolizumab combo improves OS in metastatic TNBC
MDedge Hematology and Oncology
Bevacizumab, etoposide, and cisplatin before WBRT benefits intractable breast cancer brain metastases
MDedge Hematology and Oncology
Magnetic seeds as effective as guidewire in BC patients undergoing breast-conserving surgery
MDedge Hematology and Oncology
Radiotherapy-pyrotinib-capecitabine combo benefits patients with ERBB2+ BC and brain metastases
MDedge Hematology and Oncology
Loss of progesterone receptors worsens survival in HER2− inflammatory BC
MDedge Hematology and Oncology